House To Probe FDA Knowledge Of Ranbaxy Fraud

Law360, New York (July 18, 2008, 12:00 AM EDT) -- Leaders from a U.S. House of Representatives Committee on Energy and Commerce said Thursday that they plan to launch an investigation into whether the U.S. Food and Drug Administration knowingly let Ranbaxy Inc. sell fraudulently approved and manufactured drugs.

The U.S. Department of Justice served Ranbaxy with a subpoena earlier this month that claimed reliable sources have indicated that the Indian drugmaker consistently provided the FDA with false and fabricated information about its products and attempted to hide its violations of the agency's good-manufacturing practices....
To view the full article, register now.